全文获取类型
收费全文 | 25660篇 |
免费 | 1854篇 |
国内免费 | 138篇 |
专业分类
耳鼻咽喉 | 90篇 |
儿科学 | 1485篇 |
妇产科学 | 605篇 |
基础医学 | 2215篇 |
口腔科学 | 110篇 |
临床医学 | 2501篇 |
内科学 | 7841篇 |
皮肤病学 | 463篇 |
神经病学 | 2007篇 |
特种医学 | 224篇 |
外科学 | 2950篇 |
综合类 | 607篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 2226篇 |
眼科学 | 954篇 |
药学 | 1115篇 |
2篇 | |
中国医学 | 50篇 |
肿瘤学 | 2200篇 |
出版年
2024年 | 41篇 |
2023年 | 248篇 |
2022年 | 228篇 |
2021年 | 347篇 |
2020年 | 338篇 |
2019年 | 119篇 |
2018年 | 466篇 |
2017年 | 496篇 |
2016年 | 550篇 |
2015年 | 534篇 |
2014年 | 446篇 |
2013年 | 709篇 |
2012年 | 1997篇 |
2011年 | 2271篇 |
2010年 | 795篇 |
2009年 | 774篇 |
2008年 | 2436篇 |
2007年 | 2316篇 |
2006年 | 2003篇 |
2005年 | 2088篇 |
2004年 | 2042篇 |
2003年 | 2080篇 |
2002年 | 1673篇 |
2001年 | 1250篇 |
2000年 | 284篇 |
1999年 | 137篇 |
1998年 | 199篇 |
1997年 | 116篇 |
1996年 | 90篇 |
1995年 | 57篇 |
1994年 | 72篇 |
1993年 | 36篇 |
1992年 | 41篇 |
1991年 | 32篇 |
1990年 | 37篇 |
1989年 | 36篇 |
1988年 | 36篇 |
1987年 | 39篇 |
1986年 | 33篇 |
1985年 | 24篇 |
1984年 | 24篇 |
1983年 | 11篇 |
1982年 | 17篇 |
1981年 | 19篇 |
1980年 | 12篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1974年 | 4篇 |
1970年 | 6篇 |
1957年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Wolf Szmuness Cladd E. Stevens Edward J. Harley Edith A. Zang Patricia E. Taylor Harvey J. Alter The Dialysis Vaccine Trial Group 《Journal of medical virology》1981,8(2):123-129
Three hundred thirty-six medical personnel from hemodialysis centers were treated with three doses, 20 μg each, of the Merck hepatitis B vaccine (at 0, 1, and 6 months). Within 1 month after the first injection, 41% converted to anti-HBs positivity; after the second injection the conversion rate rose to 80–90%; and after the booster, to 96–98%. The later rate remained unchanged during the 18-month follow-up period. Only 2.8% of those vaccinated did not respond to the vaccine. The patterns of immune responses to 20-μg doses were found to be exactly the same as to 40-μg doses. It is suggested that reduced doses of vaccine should be as efficacious as the larger ones. 相似文献
82.
Genetic diversity among community methicillin-resistant Staphylococcus aureus strains causing outpatient infections in Australia 下载免费PDF全文
Coombs GW Nimmo GR Bell JM Huygens F O'Brien FG Malkowski MJ Pearson JC Stephens AJ Giffard PM;Australian Group for Antimicrobial Resistance 《Journal of clinical microbiology》2004,42(10):4735-4743
Increasing reports of the appearance of novel nonmultiresistant methicillin-resistant Staphylococcus aureus MRSA (MRSA) strains in the community and of the spread of hospital MRSA strains into the community are cause for public health concern. We conducted two national surveys of unique isolates of S. aureus from clinical specimens collected from nonhospitalized patients commencing in 2000 and 2002, respectively. A total of 11.7% of 2,498 isolates from 2000 and 15.4% of 2,486 isolates from 2002 were MRSA. Approximately 54% of the MRSA isolates were nonmultiresistant (resistant to less than three of nine antibiotics) in both surveys. The majority of multiresistant MRSA isolates in both surveys belonged to two strains (strains AUS-2 and AUS-3), as determined by pulsed-field gel electrophoresis (PFGE) and resistogram typing. The 3 AUS-2 isolates and 10 of the 11 AUS-3 isolates selected for multilocus sequence typing (MLST) and staphylococcal chromosomal cassette mec (SCCmec) analysis were ST239-MRSA-III (where ST is the sequence type) and thus belonged to the same clone as the eastern Australian MRSA strain of the 1980s, which spread internationally. Four predominant clones of novel nonmultiresistant MRSA were identified by PFGE, MLST, and SCCmec analysis: ST22-MRSA-IV (strain EMRSA-15), ST1-MRSA-IV (strain WA-1), ST30-MRSA-IV (strain SWP), and ST93-MRSA-IV (strain Queensland). The last three clones are associated with community acquisition. A total of 14 STs were identified in the surveys, including six unique clones of novel nonmultiresistant MRSA, namely, STs 73, 93, 129, 75, and 80slv and a new ST. SCCmec types IV and V were present in diverse genetic backgrounds. These findings provide support for the acquisition of SCCmec by multiple lineages of S. aureus. They also confirm that both hospital and community strains of MRSA are now common in nonhospitalized patients throughout Australia. 相似文献
83.
84.
Performance and Cost evaluation of one commercial and six in-house conventional and real-time reverse transcription-pcr assays for detection of severe acute respiratory syndrome coronavirus 总被引:5,自引:0,他引:5 下载免费PDF全文
85.
Blacker D Bertram L Saunders AJ Moscarillo TJ Albert MS Wiener H Perry RT Collins JS Harrell LE Go RC Mahoney A Beaty T Fallin MD Avramopoulos D Chase GA Folstein MF McInnis MG Bassett SS Doheny KJ Pugh EW Tanzi RE;NIMH Genetics Initiative Alzheimer's Disease Study Group 《Human molecular genetics》2003,12(1):23-32
Alzheimer's disease (AD) is a devastating neurodegenerative disorder of late life with complex inheritance. Mutations in three known genes lead to the rare early-onset autosomal dominant form of AD, while a common polymorphism (epsilon 4) in the gene encoding apolipoprotein E (APOE ) is a risk factor for more typical late-onset (>60 years) AD. A recent study concluded that there are up to four additional genes with an equal or greater contribution to the disease. We performed a 9 cM genome screen of 437 families with AD, the full National Institute of Mental Health (NIMH) sample, which has been carefully ascertained, evaluated and followed by our group over the last decade. Performing standard parametric and non-parametric linkage analyses, we observed a 'highly significant' linkage peak by Lander and Kruglyak criteria on chromosome 19q13, which probably represents APOE. Twelve additional locations-on 1q23, 3p26, 4q32, 5p14, 6p21, 6q27, 9q22, 10q24, 11q25, 14q22, 15q26 and 21q22-met criteria for 'suggestive' linkage [i.e. two-point lod score (TLS) >/=1.9 and/or multipoint lod score (MLS) >/=2.2] in at least one of our analyses. Although some of these will surely prove to be false positives, these linkage signals should provide a valuable framework for future studies aimed at identifying additional susceptibility genes for late-onset AD. 相似文献
86.
BACKGROUND: The clinical efficacy and safety of a six-grass pollen allergoid has been studied. The advent of more exacting clinical guidelines and a better appreciation of the possible mechanisms of treatment prompted this reappraisal. METHODS: A 2-year double-blind multicentre placebo-controlled phase 3 clinical trial was undertaken in 154 patients suffering symptoms of rhinoconjunctivitis with or without asthma (GINA I or II). Therapy comprised two consecutive preseasonal short-courses of subcutaneous injections using a grass pollen allergoid adsorbed to aluminium hydroxide. RESULTS: A combined symptom and medication score (SMS) was used as the primary end-point for clinical efficacy. SMS from the first year showed a significant difference of 26.6% between the two study groups (P=0.026) and this was improved after the second year when there was a 48.4% difference in SMS between active and placebo treatment in favour of the allergoid (P = 0.018). Highly significant increases in grass pollen allergen-specific IgG1 and IgG4 antibody concentrations were measured in association with active treatment. Allergen tolerance was increased as judged by a conjunctival provocation test and significant improvements in quality of life were documented using a standardized questionnaire. The allergoid was well tolerated. CONCLUSIONS: The grass pollen allergoid was shown to be safe and clinically efficacious in the management of hay fever with or without asthma (GINA I or II). 相似文献
87.
George Capone Mary Stephens Stephanie Santoro Brian Chicoine Peter Bulova Moya Peterson Joan Jasien Anna Jo Smith Down Syndrome Medical Interest Group Adult Health Workgroup 《American journal of medical genetics. Part A》2020,182(7):1832-1845
Adults with Down syndrome (DS) represent a unique population who are in need of clinical guidelines to address their medical care. Many of these conditions are of public health importance with the potential to develop screening recommendations to improve clinical care for this population. Our workgroup previously identified and prioritized co‐occurring medical conditions in adults with DS. In this study, we again performed detailed literature searches on an additional six medical conditions of clinical importance. A series of key questions (KQ) were formulated a priori to guide the literature search strategy. Our KQs focused on disease prevalence, severity, risk‐factors, methodologies for screening/evaluation, impact on morbidity, and potential costs/benefits. The available evidence was extracted, evaluated and graded on quality. The number of participants and the design of clinical studies varied by condition and were often inadequate for answering most of the KQ. Based upon our review, we provide a summary of the findings on hip dysplasia, menopause, acquired cardiac valve disease, type 2 diabetes mellitus, hematologic disorders, and dysphagia. Minimal evidence demonstrates significant gaps in our clinical knowledge that compromises clinical decision‐making and management of these medically complex individuals. The creation of evidence‐based clinical guidance for this population will not be possible until these gaps are addressed. 相似文献
88.
89.
Pfaller MA Diekema DJ Messer SA Boyken L Hollis RJ Jones RN;International Fungal Surveillance Participant Group 《Journal of clinical microbiology》2003,41(1):78-83
We determined the in vitro susceptibilities of 314 strains of Candida spp., representing 13 species rarely isolated from blood, to posaconazole and voriconazole as well as four licensed systemic antifungal agents (amphotericin B, flucytosine, fluconazole, and itraconazole). The organisms included 153 isolates of C. krusei, 67 isolates of C. lusitaniae, 48 isolates of C. guilliermondii, 10 isolates of C. famata, 10 isolates of C. kefyr, 6 isolates of C. pelliculosa, 5 isolates of C. rugosa, 4 isolates of C. lipolytica, 3 isolates of C. dubliniensis, 3 isolates of C. inconspicua, 2 isolates of C. sake, and 1 isolate each of C. lambica, C. norvegensis, and C. zeylanoides. MIC determinations were made by the National Committee for Clinical Laboratory Standards reference broth microdilution method and Etest (amphotericin B). Resistance to both amphotericin B and fluconazole was observed in strains of C. krusei, C. lusitaniae, C. guilliermondii, C. inconspicua, and C. sake. Resistance to amphotericin B, but not to fluconazole, was also observed among isolates of C. kefyr and C. rugosa. Posaconazole and voriconazole were active (MIC, < or = 1 micro g/ml) against 94 to 100% of these isolates. In contrast to the more common species of Candida causing bloodstream infection, these rare species appear to be less susceptible to the currently licensed systemic antifungal agents, with the exception of voriconazole. Continued surveillance will be necessary to detect the emergence of these species as more prevalent, resistant pathogens. The new triazoles appear to offer acceptable coverage of uncommon Candida sp. bloodstream infections. 相似文献
90.
Abgrall S Matheron S Le Moing V Dupont C Costagliola D;Clinical Epidemiology Group from the French Hospital Database on HIV 《Journal of acquired immune deficiency syndromes (1999)》2001,26(2):151-158
The incidence and risk factors for Pneumocystis carinii pneumonia (PCP) recurrence were evaluated in 451 HIV-infected patients enrolled in the French Hospital Database on HIV who started highly active antiretroviral therapy (HAART) while receiving secondary PCP prophylaxis after a first episode occurring between January 1995 and December 1998. There were 18 episodes of recurrent PCP. On HAART, the CD4+ cell count increased to above 200 x 106/L in 274 patients, 51 of whom stopped PCP prophylaxis. None of these patients had PCP recurrences during 363 person-years (PY) of follow-up after the CD4+ cell count had reached 200 x 106/L (incidence rate [IR], 0.00 cases/100 PY; 95% confidence interval [CI], 0.00-0.82), and 37 PY of follow-up after the CD4+ cell count had reached 200 x 106/L and PCP prophylaxis had been discontinued (IR, 0.00 cases/100 PY; 95% CI, 0.00-7.84). The CD4+ cell count remained < 200 x 106/L in 177 patients; 9 patients stopped PCP prophylaxis, and 6 of these had a disease recurrence. Multivariate Cox analysis (time censored when CD4+ cell count > 200 x 106/L) showed that discontinuation of secondary prophylaxis (relative hazard [RH], 25.95; p <.0001) was associated with recurrence, whereas higher CD4+ cell counts during follow-up (RH, 0.39/50 x 106/L increment; p <.002) were protective. 相似文献